Tevogen to go public in $1.2bn SPAC deal
The T-cell therapeutics company expects to be listed on the NYSE after deal completion in Q4 2023.
The T-cell therapeutics company expects to be listed on the NYSE after deal completion in Q4 2023.
What's Your Reaction?
